Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits

BACKGROUND: Secondary hyperparathyroidism (SHPT) is a common complication in patients with end-stage renal disease and it is also common in hemodialysis patients. SHPT can increase bone fragility and calcification of blood vessels and soft tissues, which greatly increases the risk of death. AIM: To...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiu, Zhao, Feng, Pan, Wei-Juan, Di, Jia-Mei, Xie, Wei-Nan, Yuan, Ling, Liu, Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Clinical Trials Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638032/
https://www.ncbi.nlm.nih.gov/pubmed/34904087
http://dx.doi.org/10.12998/wjcc.v9.i33.10172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638032/
https://www.ncbi.nlm.nih.gov/pubmed/34904087
http://dx.doi.org/10.12998/wjcc.v9.i33.10172

Ejemplares similares